A non-toxic dose of MYLS22 inhibited breast cancer cells migration, proliferation and adhesion (Fig. 3a-f). These results indicate that genetic or pharmacological OPA1 inhibition reduces breast cancer cell proliferation, migration and invasiveness. Here, OPA1 is linked to breast carcinoma.